Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 97–120 of 150
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
Replacement-based interventions—substituting damaged cells, tissues, organs, and physiological systems with biological or synthetic alternatives—are emerging as a pragmatic complement to endogenous repair strategies in aging research. Multiple research organizations are advancing clinical applications ranging from stem cell therapies for structural injuries to bioprinted organs and genetic replacements derived from long-lived species.
Pharmacological reactivation of HIF-1α signaling in aged satellite cells restores lactate-driven epigenetic remodeling and shifts cells from senescence toward a regenerative state, with treated cells demonstrating enhanced myogenic capacity and increased ATP production. This identifies a metabolic-epigenetic axis relevant to age-related muscle decline and suggests a therapeutic target for sarcopenia.
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.
Fibulin-5, an extracellular matrix protein that declines with age, regulates fast-cycling skin cell populations through the YAP signaling pathway. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of regenerative cell populations and compromised dermal-epidermal integrity, suggesting this protein may be central to maintaining skin renewal capacity across the lifespan.
Fibulin-5, an extracellular matrix protein that declines with age, maintains populations of fast-cycling skin cells through YAP signaling. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of fast-cycling cells and compromised epidermal-dermal junction integrity, mirroring natural aging processes.
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Pandorum Technologies secured $18 million in Series B funding to scale its programmable tissue engineering platform for wound healing and organ repair. The capital accelerates manufacturing, regulatory pathways, and clinical partnerships for regenerative therapies addressing tissue damage and loss.
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Life Biosciences secured $80 million to advance ER-100, the first partial epigenetic reprogramming therapy entering human trials, designed to restore cellular function in age-damaged neurons. This represents a shift in aging intervention from symptom management toward addressing the underlying cellular decline that drives multiple age-related diseases.
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
Circulating stem cell count declines sharply after age 30, reducing tissue repair capacity and resilience. This decline correlates with recovery time, injury healing, and disease risk—making stem cell abundance a measurable predictor of healthspan independent of conventional longevity markers.
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.
The extracellular matrix—the structural scaffold surrounding reproductive tissues—undergoes progressive degradation during female reproductive aging, compromising ovarian function and fertility. Targeting matrix preservation and remodeling represents a mechanistic approach to extending reproductive lifespan and potentially supporting broader aging-related outcomes.
Fibulin-5, an extracellular matrix protein that declines with age, maintains epidermal stem cell function by activating YAP signaling through integrin binding. Loss of fibulin-5 reproduces age-associated changes in skin stem cell populations, identifying a molecular mechanism linking extracellular environment degradation to cellular aging.
Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.
Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
